We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Ritanserin in Treatment of Cocaine Dependence - 1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000187
Recruitment Status : Completed
First Posted : September 21, 1999
Last Update Posted : May 28, 2015
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
James Cornish, University of Pennsylvania

Brief Summary:
The purpose of this study is to assess ritanserin as a pharmacotherapy for cocaine dependence.

Condition or disease Intervention/treatment Phase
Cocaine-Related Disorders Drug: Ritanserin Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Ritanserin in Treatment of Cocaine Dependence
Study Start Date : July 1992
Primary Completion Date : June 1994

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. Cocaine use
  2. Cocaine craving

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   28 Years to 47 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Please contact site for information.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000187

United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178
Sponsors and Collaborators
University of Pennsylvania
National Institute on Drug Abuse (NIDA)
Principal Investigator: James Cornish, M.D. University of Pennsylvania

Responsible Party: James Cornish, Principal Investigator, University of Pennsylvania
ClinicalTrials.gov Identifier: NCT00000187     History of Changes
Other Study ID Numbers: NIDA-00144-1
3R01DA012268 ( U.S. NIH Grant/Contract )
First Posted: September 21, 1999    Key Record Dates
Last Update Posted: May 28, 2015
Last Verified: May 2015

Keywords provided by James Cornish, University of Pennsylvania:
Cocaine Dependence

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Serotonin Antagonists
Serotonin Agents
Antipsychotic Agents
Tranquilizing Agents
Psychotropic Drugs
Anti-Anxiety Agents
Antidepressive Agents, Second-Generation
Antidepressive Agents